Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.

Ampicillin-sulbactam Antibiotic resistance Burn Carbapenem-resistant Acinetobacter baumannii Cefiderocol Outbreak Whole-genome sequencing

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
27 Apr 2024
Historique:
received: 01 12 2023
accepted: 25 04 2024
medline: 28 4 2024
pubmed: 28 4 2024
entrez: 27 4 2024
Statut: aheadofprint

Résumé

We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry bla

Identifiants

DOI: 10.1007/s10096-024-04840-9 PMID: 38676856
pubmed: 38676856
doi: 10.1007/s10096-024-04840-9
pii: 10.1007/s10096-024-04840-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Teng J, Imani S, Zhou A, Zhao Y, Du L, Deng S et al (2023) Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother Biomedecine Pharmacother 167:115564. https://doi.org/10.1016/j.biopha.2023.115564
doi: 10.1016/j.biopha.2023.115564
Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL et al (2019) Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis IJID off Publ Int Soc Infect Dis 79:179–184. https://doi.org/10.1016/j.ijid.2018.11.371
doi: 10.1016/j.ijid.2018.11.371
Corcione S, Lupia T, De Rosa FG, Host and Microbiota Interaction Study Group (ESGHAMI) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2020) Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns Trauma 8:tkaa033. https://doi.org/10.1093/burnst/tkaa033
doi: 10.1093/burnst/tkaa033 pubmed: 32821744 pmcid: 7428410
Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD (2021) Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 76(6):1379–1391. https://doi.org/10.1093/jac/dkab015
doi: 10.1093/jac/dkab015 pubmed: 33532823
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240. https://doi.org/10.1016/S1473-3099(20)30796-9
doi: 10.1016/S1473-3099(20)30796-9 pubmed: 33058795
Mellon G, Clec’h C, Picard B, Cohen Y, Jauréguy F (2012) Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 18(6):958–960. https://doi.org/10.1007/s10156-012-0404-9
doi: 10.1007/s10156-012-0404-9 pubmed: 22430257
Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A new twist: the combination of Sulbactam/Avibactam enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) isolates. Antibiot (Basel) 10(5):577. https://doi.org/10.3390/antibiotics10050577
doi: 10.3390/antibiotics10050577
Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP et al (1985) The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 121(2):182–205. https://doi.org/10.1093/oxfordjournals.aje.a113990
doi: 10.1093/oxfordjournals.aje.a113990 pubmed: 4014115
Smoke SM, Brophy A, Reveron S, Iovleva A, Kline EG, Marano M et al (2023) Evolution and transmission of Cefiderocol-Resistant Acinetobacter baumannii during an outbreak in the burn Intensive Care Unit. Clin Infect Dis off Publ Infect Dis Soc Am 76(3):e1261–e1265. https://doi.org/10.1093/cid/ciac647
doi: 10.1093/cid/ciac647
Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J et al (2023) Clinical outcomes and bacterial characteristics of Carbapenem-resistant Acinetobacter Baumannii among patients from different global regions Clin Infect Dis. https://doi.org/10.1093/cid/ciad556
Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025
doi: 10.1016/j.cmi.2021.11.025
Gill CM, Santini D, Takemura M, Longshaw C, Yamano Y, Echols R et al (2023 Apr) In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkad032
Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel). May https://doi.org/10.3390/antibiotics10050577
Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A (2020 Jul) In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. https://doi.org/10.1099/jmm.0.001211
Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfo V, Limongi F et al (June 2023) Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization. JAC-Antimicrobial Resist 5. https://doi.org/10.1093/jacamr/dlad078

Auteurs

Emmanuel Dudoignon (E)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France. emmanuel.dudoignon@aphp.fr.
University of Paris Cité, Paris, France. emmanuel.dudoignon@aphp.fr.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France. emmanuel.dudoignon@aphp.fr.
INI-CRCT Network, Nancy, France. emmanuel.dudoignon@aphp.fr.
FHU PROMICE, Paris, France. emmanuel.dudoignon@aphp.fr.

Francois Caméléna (F)

University of Paris Cité, Paris, France.
Department of Bacteriology, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Paris, France.
INSERM 1137, IAME, Paris, France.

Matthieu Lafaurie (M)

Infectious Diseases Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.

Benjamin Deniau (B)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.
University of Paris Cité, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France.
INI-CRCT Network, Nancy, France.
FHU PROMICE, Paris, France.

Maité Chaussard (M)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Maxime Coutrot (M)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Lucie Guillemet (L)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Alexandru Cupaciu (A)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Alexandre Pharaboz (A)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Louis Boutin (L)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.
University of Paris Cité, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France.

Mourad Benyamina (M)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.

Marc Chaouat (M)

University of Paris Cité, Paris, France.
Plastic Surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.

Maurice Mimoun (M)

University of Paris Cité, Paris, France.
Plastic Surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.

Manel Merimèche (M)

Department of Bacteriology, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Paris, France.
INSERM 1137, IAME, Paris, France.

Alexandre Mebazaa (A)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.
University of Paris Cité, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France.
INI-CRCT Network, Nancy, France.
FHU PROMICE, Paris, France.

Benoit Plaud (B)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.
University of Paris Cité, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France.
FHU PROMICE, Paris, France.

Béatrice Berçot (B)

University of Paris Cité, Paris, France.
Department of Bacteriology, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Paris, France.
INSERM 1137, IAME, Paris, France.

François Dépret (F)

Department of Anesthesiology and Critical Care and Burn Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis- Lariboisière, 1, avenue Claude Vellefaux, Paris, 75010, France.
University of Paris Cité, Paris, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France.
INI-CRCT Network, Nancy, France.
FHU PROMICE, Paris, France.

Guillaume Mellon (G)

Infectious Disease Prevention and Control Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.
DMU PRISME, Paris, France.

Classifications MeSH